大塚ＨＤ アバニアファーマシューティカルズ（カリフォルニア州）を買収

大塚ＨＤ、米製薬ベンチャー買収　4200億円で
2014/12/2 22:05

大塚ホールディングス（ＨＤ）は２日、米製薬ベンチャーのアバニアファーマシューティカルズ（カリフォルニア州）を買収すると発表した。買収金額は約4200億円（35億3900万ドル）で、大塚ＨＤの買収案件では過去最大。米国で中枢神経疾患分野に本格進出し、統合失調症の大型治療薬「エビリファイ」の特許切れに伴う影響を補う。

大塚ＨＤは子会社の大塚製薬を通じ、15日までに１株あたり17ドル（約2000円）でアバニアの株式の公開買い付け（ＴＯＢ）を始め、完全子会社化を目指す。自己資金を中心に、一部借り入れも検討する。

アバニアは米ナスダックに上場。2013年９月期の売上高は約90億円（7536万ドル）、最終損益は約90億円（7547万ドル）の赤字だ。11年２月、情緒が突然不安定になる情動調節障害を治療する世界初の薬「ニューデクスタ」を発売した。アルツハイマー型認知症やパーキンソン病など中枢神経分野の新薬候補も持つ。

大塚ＨＤのエビリファイは14年３月期に5757億円を売り上げた。米国では4555億円を売るが、来年春に特許が切れるため、大幅な減収が懸念されている。
http://www.nikkei.com/article/DGXLASDZ02HNC_S4A201C1MM8000/

高すぎるような気がしますが、タイミングからして要するにそういふ事でしょうなあ・・・（爆ｗｗｗｗｗｗｗ

大塚ＨＤ会長の大塚明彦さん死去 | 匿名党 via kwout

FDA Rejects Avanir's Migraine Drug-device - Business Insider via kwout

(Reuters) - The U.S. Food and Drug Administration rejected Avanir Pharmaceuticals Inc's migraine drug device, a few weeks after the regulator had raised questions regarding some data submitted as part of the marketing application.
Earlier this month the FDA had asked Avanir to assess the root cause of errors observed in the data from the drugmaker's human factors study, which assesses if patients can use a device safely and effectively.
The product, AVP-825, delivers a low-dose sumatriptan powder - the most commonly prescribed migraine medicine - through the nose.
Avanir on Wednesday said it would conduct a new human factors study and respond to the FDA's complete response letter in the first half of next year.
The FDA was slated to decide on the product on Nov. 26.
Analysts remained confident of the product's eventual approval as the FDA only raised concerns related to the device rather than the product's active ingredient.
Cowen & Co analysts have said they expect the delay to push the launch of the drug to early 2016.
Over 37 million Americans suffer from migraines, according to the Centers for Disease Control and Prevention.
Avanir's sole treatment on the market, Nuedexta, is a treatment for pseudobulbar affect, a disorder characterized by laughing or crying that often accompanies underlying neurological disease.
The drug is also being developed for use in a host of other diseases, including Alzheimer's-related agitation as well as Parkinson's and depression.
The Aliso Viejo, California-based company's shares closed up 4 percent at a eight-year high of $15.01 on Wednesday.
The stock had risen about 14 percent since Nov. 7 when the company said the migraine drug device's approval was unlikely this year.
(Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)
Read more: http://www.businessinsider.com/r-fda-rejects-avanirs-migraine-drug-device-2014-11#ixzz3KkRY6yN3

Mr. Keith A. Katkin - Google Search via kwout

KATのKINですね、わかります。（爆ｗｗｗｗｗｗｗｗｗｗｗｗｗｗ